Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies

Blood

Volumn 124, Issue 12, 2014, Pages 1868-1872

  Storch, Emily K ^a   Hillyer, Christopher D ^a,b   Shaz, Beth H ^a,c  

^a NEW YORK BLOOD CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; CHOLINE TRANSPORTER LIKE PROTEIN 2; HUMAN NEUTROPHIL ANTIGEN 3A; HUMAN NEUTROPHIL ANTIGEN 3A ANTIBODY; PROTEIN; UNCLASSIFIED DRUG; ALLOANTIBODY; ALLOANTIGEN; CARRIER PROTEIN; HNA-3A ANTIGEN, HUMAN; MEMBRANE PROTEIN; SLC44A2 PROTEIN, HUMAN;

ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; ENZYME IMMUNOASSAY; ERYTHROCYTE; GENOTYPE; GRANULOCYTE; HUMAN; LEUKOCYTE ACTIVATION; LUNG ENDOTHELIUM; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; TRANSFUSION RELATED ACUTE LUNG INJURY; ACUTE LUNG INJURY; ADVERSE EFFECTS; BLOOD; BLOOD DONOR; BLOOD TRANSFUSION; FEMALE; GENETICS; IMMUNOLOGY; MALE; MEDICAL EDUCATION;

ACUTE LUNG INJURY; BLOOD DONORS; BLOOD TRANSFUSION; EDUCATION, MEDICAL, CONTINUING; FEMALE; GENOTYPE; HUMANS; ISOANTIBODIES; ISOANTIGENS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NEUTROPHILS;

EID: 84907225796     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-538181     Document Type: Article

References (40)

1. US Food and Drug Administration. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2013. http://www.fda.gov/BiologicsBloodVaccines/ SafetyAvailability/ReportaProblem/ TransfusionDonationFatalities/ucm391574.htm. Accessed July 15, 2014.
2. Toy P, Gajic O, Bacchetti P, et al; TRALI Study Group. Transfusion-related acute lung injury: incidence and risk factors. Blood 2012;119(7): 1757-1767.
3. Flesland O. A comparison of complication rates based on published haemovigilance data. Intensive Care Med. 2007;33(suppl 1): S17-S21.
4. Bux J. Antibody-mediated (immune) transfusionrelated acute lung injury. Vox Sang. 2011;100(1): 122-128.
5. Shaz BH, Stowell SR, Hillyer CD. Transfusionrelated acute lung injury: from bedside to bench and back. Blood 2011;117(5):1463-1471.
6. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion. 2004;44(12):1774-1789.
7. Reil A, Keller-Stanislawski B, Günay S, Bux J. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang. 2008;95(4):313-317.
8. Keller-Stanislawski B, Reil A, Günay S, Funk MB. Frequency and severity of transfusion-related acute lung injury-German haemovigilance data (2006-2007). Vox Sang. 2010;98(1):70-77.
9. US Food and Drug Administration. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2007. http://www. fda.gov/biologicsbloodvaccines/safetyavailability/ reportaproblem/transfusiondonationfatalities/ ucm118316.htm. Accessed July 15, 2014.
10. Chapman CE, Stainsby D, Jones H, et al; Serious Hazards of Transfusion Steering Group. Ten years of hemovigilance reports of transfusionrelated acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion. 2009;49(3):440-452.
11. Eder AF, Dy BA, Perez JM, Rambaud M, Benjamin RJ. The residual risk of transfusionrelated acute lung injury at the American Red Cross (2008-2011): limitations of a predominantly male-donor plasma mitigation strategy. Transfusion. 2013;53(7):1442-1449.
12. Wiersum-Osselton JC, Middelburg RA, Beckers EA, et al. Male-only fresh-frozen plasma for transfusion-related acute lung injury prevention: before-and-after comparative cohort study. Transfusion. 2011;51(6):1278-1283.
13. Lin Y, Saw CL, Hannach B, Goldman M. Transfusion-related acute lung injury prevention measures and their impact at Canadian Blood Services. Transfusion. 2012; 52(3):567-574.
14. Greinacher A, Wesche J, Hammer E, et al. Characterization of the human neutrophil alloantigen-3a. Nat Med. 2010;16(1):45-48.
15. Curtis BR, Cox NJ, Sullivan MJ, et al. The neutrophil alloantigen HNA-3a (5b) is located on choline transporter-like protein 2 and appears to be encoded by an R.Q154 amino acid substitution. Blood 2010;115(10):2073-2076.
16. Kommareddi PK, Nair TS, Thang LV, et al. Isoforms, expression, glycosylation, and tissue distribution of CTL2/SLC44A2. Protein J. 2010; 29(6):417-426.
17. Bayat B, Tjahjono Y, Sydykov A, et al. Anti-human neutrophil antigen-3a induced transfusion-related acute lung injury in mice by direct disturbance of lung endothelial cells. Arterioscler Thromb Vasc Biol. 2013;33(11):2538-2548.
18. Flesch BK, Wesche J, Berthold T, et al. Expression of the CTL2 transcript variants in human peripheral blood cells and human tissues. Transfusion. 2013;53(12):3217-3223.
19. Kommareddi PK, Nair TS, Vallurupalli M, et al. Autoantibodies to recombinant human CTL2 in autoimmune hearing loss. Laryngoscope. 2009; 119(5):924-932.
20. Davoren A, Curtis BR, Shulman IA, et al. TRALI due to granulocyte-agglutinating human neutrophil antigen-3a (5b) alloantibodies in donor plasma: a report of 2 fatalities. Transfusion. 2003; 43(5):641-645.
21. Fadeyi EA, De Los Angeles Muniz M, Wayne AS, Klein HG, Leitman SF, Stroncek DF. The transfusion of neutrophil-specific antibodies causes leukopenia and a broad spectrum of pulmonary reactions. Transfusion. 2007;47(3): 545-550.
22. Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA. 2002;287(15):1968-1971.
23. Silliman CC, Curtis BR, Kopko PM, et al. Donor antibodies to HNA-3a implicated in TRALI reactions prime neutrophils and cause PMN-mediated damage to human pulmonary microvascular endothelial cells in a two-event in vitro model. Blood 2007;109(4):1752-1755.
24. Seeger W, Schneider U, Kreusler B, et al. Reproduction of transfusion-related acute lung injury in an ex vivo lung model. Blood 1990;76(7): 1438-1444.
25. Grimminger F, Kreusler B, Schneider U, et al. Human leukoagglutinating antibody evokes cooperative leukotriene synthesis in pulmonary microvasculature. Model of transfusion-related acute lung injury. Circ Res. 1991;68(2):503-512.
26. Thomas GM, Carbo C, Curtis BR, et al. Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. Blood 2012;119(26):6335-6343.
27. Caudrillier A, Kessenbrock K, Gilliss BM, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest. 2012;122(7):2661-2671.
28. Saffarzadeh M, Juenemann C, Queisser MA, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS ONE. 2012; 7(2):e32366.
29. Segel GB, Halterman MW, Lichtman MA. The paradox of the neutrophil's role in tissue injury. J Leukoc Biol. 2011;89(3):359-372.
30. Bougie DW, Peterson JA, Kanack A, Curtis BR, Aster RH. Antibodies specific for human neutrophil antigen 3a (HNA-3a) recognize complex epitopes on choline transporter protein 2 (CTL2): implications for HNA-3a antibody detection. Blood 2013;122(21). Abstract 3662.
31. Silliman CC, Kelher MR, Khan SY, et al. Experimental prestorage filtration removes antibodies and decreases lipid bioactivity accumulation in RBC supernatants mitigating TRALI in vivo. Blood 2014;123(22):3488-3495.
32. Bowens KL, Sullivan MJ, Curtis BR. Determination of neutrophil antigen HNA-3a and HNA-3b genotype frequencies in six racial groups by high-throughput 59 exonuclease assay. Transfusion. 2012;52(11):2368-2374.
33. Reil A, Wesche J, Greinacher A, Bux J. Genoand phenotyping and immunogenicity of HNA-3. Transfusion. 2011;51(1):18-24.
34. Bierling P, Bux J, Curtis B, et al; ISBT Working Party on Granulocyte Immunobiology. Recommendations of the ISBT Working Party on Granulocyte Immunobiology for leucocyte antibody screening in the investigation and prevention of antibody-mediated transfusionrelated acute lung injury. Vox Sang. 2009;96(3): 266-269.
35. Kleinman S, Grossman B, Kopko P. A national survey of transfusion-related acute lung injury risk reduction policies for platelets and plasma in the United States. Transfusion. 2010;50(6): 1312-1321.
36. Wózniak MJ, Bowring C, Lucas G, Ridgwell K. Detection of HNA-3a and-3b antibodies using transfected cell lines and recombinant proteins. Transfusion. 2012;52(7): 1458-1467.
37. Curtis BR, Sullivan MJ, Holyst MT, Szabo A, Bougie DW, Aster RH. HNA-3a-specific antibodies recognize choline transporter-like protein-2 peptides containing arginine, but not glutamine at position 154. Transfusion. 2011; 51(10):2168-2174.
38. Berthold T, Wesche J, Kuhnert K, et al. Epitope mapping of antibodies directed against the human neutrophil alloantigen 3a. Transfusion. 2011; 51(10):2160-2167.
39. Bayat B, Tjahjono Y, Werth S, et al. Implication of transfected cell lines for the detection of alloantibodies against human neutrophil antigen-3. Transfusion. 2012;52(3):613-621.
40. Kanack AJ, Peterson JA, Sullivan MJ, Bougie DW, Curtis BR, Aster RH. Full-length recombinant choline transporter-like protein 2 containing arginine 154 reconstitutes the epitope recognized by HNA-3a antibodies. Transfusion. 2012;52(5): 1112-1116.